株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

世界における循環腫瘍細胞と癌幹細胞技術

Circulating Tumor Cells and Cancer Stem Cells Technologies

発行 Global Industry Analysts, Inc. 商品コード 301517
出版日 ページ情報 英文 213 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
世界における循環腫瘍細胞と癌幹細胞技術 Circulating Tumor Cells and Cancer Stem Cells Technologies
出版日: 2014年03月01日 ページ情報: 英文 213 Pages
概要

当レポートでは、世界の循環腫瘍細胞と癌幹細胞技術市場について調査し、地域別の包括的動向、2013〜2020年の予測、参入企業のプロファイルをまとめ、概略下記の構成で取り上げております。

第1章 イントロダクション、調査方法、製品定義

第2章 エグゼクティブサマリー

  • 循環腫瘍細胞(CTC):世界市場概要
    • CTCの検出
    • CTC診断の課題
    • CTC濃縮の必要性と定評ある手法
    • CTC同定:様々なアプローチ
    • CTC同定アプローチ
    • 市場見通し
    • 癌の発症率上昇
    • 年齢別癌になりやすい部位
  • 市場動向と促進因子
  • 癌幹細胞:世界市場概要
    • 癌治療における癌幹細胞技術革新
    • 癌幹細胞候補のための経路または分子標的
    • 眼科医細胞治療のパイプライン分析
    • 癌幹細胞マーカーに対する標的毒性
    • 癌幹細胞の隔離に用いられる様々な方法
    • 抗体媒体治療
  • 循環腫瘍細胞と癌幹細胞研究結果と画期的成果
  • 医療診断市場:概要
    • 臨床診断
    • 分子診断
    • 悪性リンパ腫のための分子診断
    • 市場動向と課題
    • 世界の急成長する分子診断
    • 自動化が促進する市場 他
  • 循環腫瘍細胞診断:濃縮、同定、特性化手法
  • 癌幹細胞:生物学、隔離、表面マーカー、信号伝達経路
  • 製品上市とイントロダクション
  • 近年の業界の動き
  • 循環腫瘍細胞診断の主要参入企業
    • Adnagen GmbH
    • ApoCell, Inc
    • Biocep LTD
    • Biocept, Inc.
    • Biofluidica Microtechnologies LLC
    • Celltrafix Inc.
    • Clearbridge Biomedics
    • Creatv Microtech, Inc
    • Cynvenio Biosystems, Inc.
    • Ikonisys, Inc.
    • IVDiagnostics, Inc.
    • Janssen Diagnostics LLC
    • Epic Biosciences Inc
    • RARECELLS SAS
    • SCREENCELL
    • Stemcell Technologies, Inc.
  • 癌幹細胞分野の市場参入企業
    • Alchemia Limited
    • Amgen Inc.
    • Exelixis, Inc.
    • Formula Pharmaceuticals
    • GlaxoSmithKline Plc.
    • Geron Corp.
    • Infinity Pharmaceuticals
    • Kalobios Pharmaceuticals Inc.
    • Novartis AG
    • OncoMed Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • Roche Diagnostics
    • Verastem, Inc.
  • 世界市場見通し

第3章 市場

  • 米国
  • カナダ
  • 日本
  • 欧州
  • アジア太平洋地域
  • その他

第4章 競合環境

目次
Product Code: MCP-7869

This report analyzes the worldwide markets for Circulating Tumor Cells and Cancer Stem Cells Technologies in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 66 companies including many key and niche players such as -

  • Alchemia Limited
  • Amgen Inc.
  • Exelixis, Inc.
  • Formula Pharmaceuticals
  • GlaxoSmithKline Plc

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. CIRCULATING TUMOR CELLS (CTCS) - GLOBAL MARKET OVERVIEW

  • CTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical Biopsy
  • Challenges in CTC Diagnostics
  • Need for CTC Enrichment and Popular Methods
  • CTC Enrichment Techniques
  • CTC Identification - Various Approaches
  • CTC IDENTIFICATION APPROACHES
  • A List of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor Type
  • CellSearch System?- The Only FDA Approved Automated Enrichment/Isolation Technique
  • Market Outlook
  • Rising Incidence of Cancer - An Opportunity Indicator
    • Table 1: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 2: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer-Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 3: New Cancer Cases in the World by Affected Site: 2012 (in Thousands) (includes corresponding Graph/Chart)
    • Table 4: Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in Thousands for Lung & Bronchus, Prostate, Colorectal and Liver Cancers (includes corresponding Graph/Chart)
    • Table 5: Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in Thousands for Breast, Colorectal, Lung & Bronchus and Liver Cancers (includes corresponding Graph/Chart)
    • Table 6: Global Cancer Mortality in Men for Select Cancers (2012): Number of Deaths in Thousands for Lung & Bronchus, Liver, Colorectal and Prostate Cancers (includes corresponding Graph/Chart)
    • Table 7: Global Cancer Mortality in Women for Select Cancers (2012): Number of Deaths in Thousands for Breast, Lung & Bronchus, Colorectal and Liver (includes corresponding Graph/Chart)
  • Cancer Prone Sites based on Age

2. MARKET TRENDS AND DRIVERS

  • CTCs for Personalized Cancer Treatment
  • Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis
  • CTC Microdevices Hog the Limelight
    • Table 8: Select CTC Microdevices and Their Characteristics
  • Limitations of CTC Technology for Point-of-Care Testing
  • CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis
  • Limited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth?

3. CANCER STEM CELLS - GLOBAL MARKET OVERVIEW

  • CSC-Focused Innovations in Cancer Therapeutics
  • Select Pathways or Molecular Targets for CSC Candidates
  • Pipeline Analysis of Select Cancer Stem Cells Therapeutics (2014)
  • Select Targeted Toxins against CSC Markers: 2013
  • Various Methods Used for Isolation of Cancer Stem Cells
  • Antibody-mediated Therapies

4. CTC AND CSC RESEARCH FINDINGS & BREAKTHROUGHS

  • Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity
  • Nbiomics Makes its Contribution to CTC Diagnosis
  • Researchers at University of Michigan Develop Revolutionary Capture CTCs Method
  • Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis
  • Gold Nanoparticles Help in the Detection of CTCs
  • Diabetes Drug Metformin May Prove Effective against Pancreatic Cancer Stem Cells
  • Novel Chemical Inhibitors that Target Cancer Stem Cells

5. MEDICAL DIAGNOSTICS MARKET - A CONCEPTUAL OVERVIEW

  • Clinical Diagnostics
    • Table 9: Leading Players in the Global In Vitro Diagnostics (IVD) Market (2013) - Market Share Breakdown by Value Sales for Roche Diagnostics, Abbott Laboratories, Siemens, J&J, Beckman Coulter, bioMerieux, and Others (includes corresponding Graph/Chart)
    • Table 10: Global In-Vitro Diagnostics (IVD) Market (2013): Percentage Breakdown for Value Sales by Segment for Point of Care, Immunity Tests, Clinical Chemistry, Nucleic Acid Tests, Histology/Cytology, Microbiology, Haematology and Others (includes corresponding Graph/Chart)
  • Molecular Diagnostics - Growth Drivers
  • Molecular Diagnostics for Lymphoid Malignancies
  • Market Trends & Issues
  • Global Molecular Diagnostics on a High Growth Curve
  • Automation Driving Global Market
  • Molecular Diagnostics: Marking Convergence of Numerous Technologies
  • Aging Population, Disease Incidence - Fundamental Drivers of Growth
  • Pharmaceutical Firms Carving their Niche in the Molecular Diagnostics Market
  • Limited Reimbursements by Third Party Payers - A Stumbling Block
  • Molecular Diagnostics and Intellectual Property
  • Business Opportunities in the Offing
  • Medical Training and Practice Challenges
  • Hurdles All the Way for Companies Eyeing Molecular Diagnostics
  • Integration of Molecular Diagnostics into Therapeutics
  • Molecular Diagnostics - Moving from Centralization to Decentralization

6. CIRCULATING TUMOR CELL (CTC) DIAGNOSTICS - ENRICHMENT, IDENTIFICATION AND CHARACTERIZATION METHODS

  • Introduction
  • Enrichment
  • Filtration (iSET)
  • Density Gradient
  • Immuno-magnetic Cell Enrichment
    • Advantages of Different CTC Enrichment Procedures
  • AdnaTest
  • Identification
  • 1. PCR-Based Analysis
      • Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
      • RT-qPCR
  • 2. Cytometric Methods
      • Fiber-Optic Array Scanning Technology (FAST)
      • Laser Scanning Cytometry (LSC)
      • Flow Cytometry
      • CellSearch
      • CTC-Chip
      • Enzyme-linked Epithelial Immunospot Assay (ELISPOT)
      • Fluorescence In Situ Hybridization (FISH)
      • Vita-AssayR
      • TelomeScan?
      • CytoTrack
      • Some Other Methods for Detection of CTCs
  • Characterization
  • Chemo-Sensitivity Testing of CTCs

7. CANCER STEM CELLS (CSCS) - BIOLOGY, ISOLATION, CSC SURFACE MARKERS, AND SIGNALING PATHWAYS

  • Introduction
  • Differences between Normal Stem Cells and Cancer Stem Cells
  • Milestones in Stem Cell and Cancer Stem Cell Research
  • Origin
  • Hierarchical versus Stochastic Models of Tumour Cell Heterogeneity
  • Isolation of Cancer Stem Cells
  • Characteristics of Cancer Stem Cells
  • Resistance to Chemotherapy
  • Resistance to Radiation
  • Invasion or Metastatic Activity
  • CSC Markers
  • EpCAM (Epithelial Cell Adhesion Molecule)
  • CD133 (prominin 1)
  • ALDH
  • CD90 (THY1)
  • CD44 (PGP1)
  • CD24 (HAS)
    • Surface Markers Used for the Identification of CSCs
    • Cancer Stem Cell (CSC) Markers by Disease
  • Metastatic Cancer Stem Cells
    • Table 11: Cancer Stem Cells in Solid Tumors
  • Pathways Involved in the Maintenance of CSCs
  • p53 Pathway
  • Activation of Receptor Tyrosine Kinase Pathway
  • Notch Pathway
  • Retinoblastoma Pathway
  • Wnt and Sonic Hedgehog Pathways
  • BMI-1
  • Research Indicates Diabetes Drug Metformin Effective against Pancreatic Cancer Stem Cells
  • Research Leads to Development of Novel Chemical Inhibitors that Target Cancer Stem Cells

8. PRODUCT LAUNCHES AND INTRODUCTIONS

  • EU Authorisation for ANGLE's Parsortix Cancer Diagnostic Device
  • ANGLE Launches Parsortix Device into the Research Market
  • Promab Introduces New Range of Cancer Stem Cells Solutions
  • Clearbridge BioMedics Unveils ClearCellR FX Cancer Cell Enrichment System
  • Fluxion Introduces New IsoFlux System CTC Technology
  • Cynvenio Launches LiquidBiopsy Lab Service
  • Biocept Launches OncoCEE-BR
  • ApoCell to Launch ApoStream

9. RECENT INDUSTRY ACTIVITY

  • Stem Cell Therapeutics and University of York Ink Option Agreement
  • Veridex Undergoes Name Change to Janssen Diagnostics
  • Janssen Diagnostics and Arno Therapeutics Ink Collaboration Agreement
  • Veridex Enters into Agreement with LabCorp
  • Stemline Therapeutics Obtains Orphan Drug Designation for SL-401
  • ANGLE Announces Test Results of Parsortix Non-Invasive Cancer Diagnostic Product
  • University Health Network Signs Definitive License Agreement with Stem Cell Therapeutics
  • Verastem Inks Agreement with LabCorpR
  • Verastem Receives Orphan Drug Designation for Defactinib from US FDA
  • Lonza Partners with Eclipse
  • Verastem Signs Agreement with Pfizer to Acquire Exclusive In-License Rights for VS-6063
  • ScreenCell Inks Global Distribution Agreement with Affymetrix
  • Dainippon Sumitomo Pharma to Take Over Boston Biomedical
  • Bionomics Takes Over Eclipse Therapeutics
  • BioView Signs Commercial Collaboration Agreement with ScreenCell
  • Coare Enters into a Services and Co-Marketing Alliance with ChemDiv
  • Eisai Signs Research Agreement with Verastem
  • Fluxion Biosciences Inks Collaboration Agreement with Rubicon Genomics
  • Transgenomic Enters into Partnership with MD Anderson Cancer Center
  • Transgenomic Collaborates with NYU Langone Medical Center
  • Veridex Receives China SFDA Approval for CellSearchR CTC Test for Breast Cancer
  • ScreenCell Signs Global Collaboration and Distribution Agreement with Transgenomic
  • OncoMed Pharmaceuticals Extends Collaboration with Bayer Healthcare for New Cancer Drug
  • Veridex Partners with Massachusetts General Hospital for CTC Technology

10. FOCUS ON SELECT MAJOR PLAYERS IN CTC DIAGNOSTICS

  • Adnagen GmbH (Germany)
  • ApoCell, Inc (US)
  • Biocep LTD (Israel)
  • Biocept, Inc. (US)
  • Biofluidica Microtechnologies LLC (US)
  • Celltrafix Inc. (US)
  • Clearbridge Biomedics (Singapore)
  • Creatv Microtech, Inc (US)
  • Cynvenio Biosystems, Inc. (US)
  • Ikonisys, Inc. (US)
  • IVDiagnostics, Inc. (US)
  • Janssen Diagnostics LLC (US)
  • Epic Biosciences Inc (US)
  • RARECELLS SAS (Italy)
  • SCREENCELL (France)
  • Stemcell Technologies, Inc. (Canada)

11. SELECT MARKET PARTICIPANTS IN THE CANCER STEM CELLS (CSCs) SPACE

  • Alchemia Limited (Australia)
  • Amgen Inc. (US)
  • Exelixis, Inc. (US)
  • Formula Pharmaceuticals (US)
  • GlaxoSmithKline Plc. (UK)
  • Geron Corp. (US)
  • Infinity Pharmaceuticals (US)
  • Kalobios Pharmaceuticals Inc. (US)
  • Novartis AG (Switzerland)
  • OncoMed Pharmaceuticals, Inc. (US)
  • Pfizer, Inc. (US)
  • Roche Diagnostics (Switzerland)
  • Verastem, Inc. (US)

12. GLOBAL MARKET PERSPECTIVE

    • Table 12: World Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 13: World Historic Review for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 14: World 15-Year Perspective for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • US Diagnostics Market: An Overview
    • CTC Diagnostics in the US - Set for a Strong Growth
    • Cancer Incidence in the US
    • Table 15: New Cancer Cases in the US by Gender and Affected Site: 2012
    • Table 16: New Cancer Cases in Males in US by Leading Site: 2012 (includes corresponding Graph/Chart)
    • Table 17: New Cancer Cases in Females in US by Leading Site: 2012 (includes corresponding Graph/Chart)
    • Research Breakthroughs in the US CTC Market
    • Product Launches
    • Strategic Corporate Development
    • Select Key Players in CTC Market
    • Select Key Players in CSC Market
  • B. Market Analytics
    • Table 18: The US Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 19: The US Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Cancer Incidence in Canada
    • Table 20: New Cancer Cases in Canada by Gender and Affected Site: 2012 (includes corresponding Graph/Chart)
    • Table 21: New Cancer Cases in Canada by Province: 2012 (includes corresponding Graph/Chart)
    • Table 22: New Cancer Cases in Canada by Age Group: 2012 (includes corresponding Graph/Chart)
    • Strategic Corporate Development
    • Stemcell Technologies, Inc. - A Key Player
  • B. Market Analytics
    • Table 23: Canadian Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 24: Canadian Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 25: Japanese Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 26: Japanese Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Insight into Molecular Diagnostics Markets in Europe
    • Table 27: European IVD Market for Select Countries (2010) - Market Value in US$ Million for Spain, UK, Germany, Italy, France, Poland, Netherlands, Belgium, Denmark, Portugal, Austria, Sweden, Bulgaria and Lithuania (includes corresponding Graph/Chart)
    • Debt Crisis in Europe Affects Healthcare Industry
    • Healthcare System.... In a State of Transition?
    • Cancer Trends
    • Table 28: Cancer Incidence in Europe by Site: 2012 (in Thousands) (includes corresponding Graph/Chart)
    • ANGLE's Parsortix Cancer Diagnostic Device Obtains EU Approval
  • B. Market Analytics
    • Table 29: European Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 30: European Historic Review for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)
    • Table 31: European 15-Year Perspective for Circulating Tumor Cells (CTCs) Diagnostics by Geographic Region - Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2006, 2014 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Screencell - A Key Player
  • B. Market Analytics
    • Table 32: French Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 33: French Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • An Overview of Molecular Diagnostics
    • Key Player
  • B. Market Analytics
    • Table 34: German Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 35: German Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Rarecells Sas - A Key Player
  • B. Market Analytics
    • Table 36: Italian Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 37: Italian Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Product Launch
    • Strategic Corporate Developments
    • GlaxoSmithKline Plc. - A Key Company Focusing on CSC Therapeutics
  • B. Market Analytics
    • Table 38: The UK Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 39: The UK Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4e. SPAIN

  • Market Analysis
    • Table 40: Spanish Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 41: Spanish Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4f. RUSSIA

  • Market Analysis
    • Table 42: Russian Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 43: Russian Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Select Players in CSC Markets
  • B. Market Analytics
    • Table 44: Rest of Europe Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 45: Rest of Europe Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Cancer Trends in Asia-Pacific
    • Table 46: Cancer Incidence in Asia-Oceania by Site: 2011 (in Thousands) (includes corresponding Graph/Chart)
    • India
    • China
      • CellSearch Obtains Approval for Metastatic Breast Cancer Detection in China
    • Product Launch
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 47: Asia-Pacific Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 48: Asia-Pacific Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Key Player
  • B. Market Analytics
    • Table 49: Rest of World Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2013 Through 2020 (includes corresponding Graph/Chart)
    • Table 50: Rest of World Historic Review for Circulating Tumor Cells (CTCs) Diagnostics Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2012 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top